Navigation Links
TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
Date:6/4/2008

LA JOLLA, Calif., June 4 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced it has initiated a clinical trial to evaluate the analgesic effect of NGX426, the oral prodrug of its lead product candidate, tezampanel.

The randomized, double-blind, placebo-controlled Phase I trial will enroll 18 healthy volunteers at a single center in the United States. The trial is designed to evaluate the compound's safety and tolerability and to assess the time of onset, magnitude and duration of its analgesic effect. Specifically, the study will evaluate the effect of NGX426 on hyperalgesia, an abnormally increased pain state, and allodynia, pain resulting from normally non-painful stimuli to the skin, induced by intradermal injections of capsaicin. The primary endpoint is subject self-report of spontaneous pain following the injection of capsaicin.

"We believe there is a substantial commercial opportunity for NGX426 as a novel, oral analgesic," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines Therapeutics. "Data we have obtained in our ongoing Phase I maximum tolerated dose study demonstrate that the drug is well-tolerated at single doses up to and including 210 mg and that NGX426 is rapidly converted to tezampanel. Moreover, this capsaicin study, if successful, will enable us to further take advantage of the versatility of NGX426 and the overall tezampanel franchise."

Subjects in the trial, which involves the recognized and validated capsaicin-induced pain model, will receive single doses of 90 mg and 150 mg of NGX426 versus placebo in a three-way crossover design.

Tezampanel is the first AMPA/kainate-type glutamate receptor antagonist to be studied in clinical t
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
2. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
3. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
4. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
5. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
9. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
10. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
11. Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... -- Ellen MacArthur Foundation meddelade i ... kommer att vara en partner för att hjälpa ... Efter stiftelsens framgångsrika partnerskap med Renault, BT/Cisco ... att ansluta sig som partner för att få ... verksamhet och stödja stiftelsens arbete inom utbildning. ...
(Date:6/19/2013)... , June 19, 2013 The Physician-Patient Alliance ... alarm fatigue. The need to urgently address this ... its Sentinel Event Alert #50 , "Medical device alarm safety ... database, between January 2008 and June 2012, there were 98 ... resulted in death (82%) , 13 resulted in permanent ...
(Date:6/19/2013)...   BioCision , a leader in advanced ... many areas of medical and scientific research, announced ... U.S. Patent Office that apply to two of ... handling to ensure the consistency of test conditions ... Patent number 8,388,912 covers CoolSink® ...
Breaking Medicine Technology:Ellen MacArthur Foundation presenterar Philips som global partner vid det konstituerande internationella toppmötet om cirkulär ekonomi 2Ellen MacArthur Foundation presenterar Philips som global partner vid det konstituerande internationella toppmötet om cirkulär ekonomi 3Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 2Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 3BioCision Announces Two New U.S. Patents for Thermo-Conductive Products that Standardize Sample Handling in Laboratory Research 2
... Inc. (Nasdaq: KERX ) today announced that ... from previous clinical trials of Zerenex™ (ferric citrate) were ... the American Society of Nephrology (ASN) Kidney Week 2011 ... ferric iron-based drug candidate, is currently in Phase 3 ...
... and WASHINGTON, Nov. 14, 2011 Nektar Therapeutics (NASDAQ: ... data for NKTR-192, a novel mu-opioid agonist, was presented ... Neuroscience being held November 12-16, 2011 in Washington, DC. ... for the treatment of acute pain.  It is designed ...
Cached Medicine Technology:Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting 2Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting 3Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting 4Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011 2Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011 3Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011 4Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011 5Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011 6
(Date:6/19/2013)... 19, 2013 The Journal of Parasitology ... today’s computer software, it creates questions of ethics. For ... As an already published case shows, scientific publications need ... The Journal of Parasitology features a ... a 2004 article published in the Journal of the ...
(Date:6/19/2013)... HOUSTON - In a major international study led by ... Center, the targeted therapy ibrutinib continues to show remarkable ... cell lymphoma (MCL). , The most recent interim findings ... in the New England Journal of Medicine . ... the 54th American Society of Hematology Annual Meeting and ...
(Date:6/19/2013)... published in the June 19 online edition of the ... researchers from the University of California, San Diego School ... take place when cardiac regeneration occurs in zebrafish after ... various cell lines in the heart are more plastic, ... previously thought. , More importantly, the research reveals a ...
(Date:6/19/2013)... understanding of the genetic process that can lead to ... lesions for some women, and also raises a warning ... cases suggesting they could actually trigger the cancer ... a clearer picture of the chromosomal and genetic changes ... to chronic infection and, in less than 1 percent ...
(Date:6/19/2013)... University of Iowa study reveals significant disparities between ... completing substance abuse treatment programs. Moreover, these disparities ... "Our findings suggest that for most states there,s ... of psychiatry and biostatistics. "There are strong racial ... to complete substance abuse treatment programs successfully, and ...
Breaking Medicine News(10 mins):Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2Health News:Fate of the heart: Researchers track cellular events leading to cardiac regeneration 2Health News:Genetics of cervical cancer raise concern about antiviral therapy in some cases 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3
... out-of-pocket health care costs, CAMP HILL, Pa., Sept. ... to help consumers compare health plan options and,choose one ... is available,to consumers on Highmark member Web sites. ... said Kim,Bellard, Vice President of eMarketing and Customer Relationship ...
... President, SEIU-UHW and SEIU California State ... ... My name is Sal Rosselli,and I,m the President of SEIU United ... workers in healthcare, the,public sector, property services, and other industries throughout ...
... choices , MONDAY, Sept. 10 (HealthDay News) -- U.S. and ... a comprehensive recommendation on how much of what types of ... diets. , Both the American Dietetic Association and the Dietitians ... that 20 percent to 30 percent of energy needs should ...
... -- In lifesaving procedures to open blocked heart arteries ... use of the more expensive drug, abciximab, justified over ... Mayo Clinic study to be published in the current ... and now available as an e-publication, offers clinicians the ...
... Hundreds of Institutional Investors to Attend Conference, ... Board: SKVI / Website: http://www.skinvisible.com ), the ... topically,applied dermatology products, today announced that Mr. Terry ... annual Merriman Curhan Ford & Co.,Investor Summit on ...
... Through November 2007 -, GLENDALE, Calif., ... for applications for the 2008-2009 PowerBar Team ... athletes, coaches,nutritionists, trainers and health and fitness ... invited to visit, http://www.powerbar.com/teamelite/application to submit ...
Cached Medicine News:Health News:Highmark Blue Shield Introduces New Health Plan Comparison Tool for Consumers 2Health News:SEIU Endorses AB 8, 'An Opportunity to Make History' 2Health News:Experts Sort Out Good Fats From Bad 2Health News:Skinvisible to Present at Merriman Curhan Ford & Co.'s Investor Summit 2007 2Health News:PowerBar Issues Open Call for 2008-2009 PowerBar Team Elite(TM) Athlete Sponsorship Program 2
... MacularProtect Complete® is a scientifically ... protection for macular and full body ... the AREDS clinical trial and other ... multinutrient component that provides a broad ...
... formulation that provides the foundation for ... eye-specific nutritional support. All ingredients in ... when applicable. ScienceBased Health formulations are ... bioavailability, and are free of artificial ...
HydroEye is an exclusive formulation designed to provide dry eye relief and support the body's natural tear formation. Like all ScienceBased Health formulations, it is produced in softgel form for ma...
Online Unity Interlaboratory QC Data Management...
Medicine Products: